- DE SA KSG, Silva J, Bayarri-Olmos R, Baker CA, et al
A causal link between autoantibodies and neurological symptoms in long COVID.
Cell. 2026;189:3214-3235.
PubMed Abstract available - WALL EC, Richter AG
Autoantibodies in long COVID: A mechanistic foothold in a heterogeneous disease.
Cell. 2026;189:3179-3180.
PubMed Abstract available - FOURNIER M, Vanderkerken M, Dorgham K, Bastard P, et al
Affinity-matured B cell responses neutralizing type-I interferons underlie severe viral infections.
Cell. 2026;189:3236-3253.
PubMed Abstract available - KITAMURA N, Kondo N, Ith S, Okuyama M, et al
Post-pandemic immunity debt for paediatric infectious diseases in Japan between 2014 and 2024.
Epidemiol Infect. 2026;154:e67.
PubMed Abstract available - WANG Q, McManus LR, Levine KS, Blanc R, et al
A multiplexed, systems-based approach for prediction of antibody neutralization breadth for soluble human receptors.
J Immunol. 2026;215:vkag106.
PubMed Abstract available - WEE LE, Ho RWL, Lim JT, Lim SK, et al
Real-world effectiveness of influenza vaccination amongst children aged under 5 in a tropical setting.
J Infect. 2026 May 26:106771. doi: 10.1016/j.jinf.2026.106771.
PubMed Abstract available - MUNRO AP, Ferrari M, Kinsley R, Egan D, et al
A phase I, needle free, dose escalation clinical trial of pEVAC-PS, a candidate pan-Sarbecovirus Vaccine.
J Infect. 2026 May 18:106759. doi: 10.1016/j.jinf.2026.106759.
PubMed Abstract available - KIM HK, Jo S, Min KD, Cho SI, et al
Effectiveness of bivalent COVID-19 vaccines against SARS-CoV-2 reinfection in Patients With Cancer: Evidence From a Nationwide Target Trial Emulation.
J Infect. 2026 Apr 28:106753. doi: 10.1016/j.jinf.2026.106753.
PubMed Abstract available - LOES AN, Tarabi RAL, Li SH, Atkinson RK, et al
Strain-specific differences in the response to egg-derived versus recombinant protein influenza vaccines.
J Virol. 2026 May 27:e0031726. doi: 10.1128/jvi.00317.
PubMed Abstract available - ZENG Q, Liu L, Wang T, Zhang C, et al
Artificial intelligence-assisted technology to reduce turnaround time for rapid diagnosis of infectious diseases.
J Virol Methods. 2026;344:115392.
PubMed Abstract available - ZHOU F, Periasamy S, Jackson ND, Cheng WS, et al
Redundant and distinct mechanisms suppress innate immune activation during SARS-CoV-2 infection.
PLoS Biol. 2026;24:e3003808.
PubMed Abstract available - JANSEN E, Bockstal V, Herschke F, Olsson Gisleskog P, et al
Characterization of the VHH-Fc construct rimteravimab in healthy adults and patients hospitalized for mild-to-moderate COVID-19: Two Phase 1 randomized clinical trials.
PLoS Med. 2026;23:e1004609.
PubMed Abstract available - SILVA-VALENCIA J, Tu K, Moineddin R, Butt DA, et al
Trends in pulmonary exercise testing utilization after the COVID-19 pandemic in Ontario: A population-cohort study.
PLoS One. 2026;21:e0349020.
PubMed Abstract available - WARNE DJ, Varghese A, Brewster A, Browning AP, et al
Bayesian uncertainty quantification to identify population level vaccine hesitancy behaviours.
PLoS One. 2026;21:e0349499.
PubMed Abstract available - AKIN HY, Tuncali T, Gencer EB, Cengiz Seval G, et al
Innate immunogenetic synergy between KIR and Neanderthal-derived OAS variants predicts COVID-19 outcomes.
PLoS One. 2026;21:e0345137.
PubMed Abstract available - SIROTIAK Z, Oberhauser AM, Sirotiak AM, Nettleton KA, et al
Exploring the perceived impact of physical activity on physical and mental health among individuals with long COVID: A qualitative interview inquiry.
PLoS One. 2026;21:e0350121.
PubMed Abstract available - FIORE E, Taio G, Morandi N, Mazzotta E, et al
Lung ultrasonography to assess efficacy of intranasal and parenteral vaccinations for bovine respiratory disease (BRD) in dairy calves.
PLoS One. 2026;21:e0349953.
PubMed Abstract available - AGYEI G, El-Duah P, Dumevi RM, Muzeniek T, et al
Serological responses to SARS-CoV-2 in urban and rural Ghana: Antibody waning and implications for long-term population immunity.
PLoS One. 2026;21:e0348281.
PubMed Abstract available - ROSSI SL, Cheng DM, Sereda Y, Truong V, et al
COVID-19 pandemic-related stress and substance use behaviors among people with HIV - a mixed method analysis.
PLoS One. 2026;21:e0349567.
PubMed Abstract available - YEO HY, Park JY, Marsh S, Castelino L, et al
Evidence mapping of preference elicitation for non-pharmaceutical interventions targeting respiratory viral transmission: A scoping review protocol.
PLoS One. 2026;21:e0344828.
PubMed Abstract available - KUBILIUTE I, Zaboras E, Majauskaite F, Urboniene J, et al
Predicting severe COVID-19 disease in adults: A single-centre cohort study during the first three pandemic waves in 2020-2021 in Vilnius, Lithuania.
PLoS One. 2026;21:e0350112.
PubMed Abstract available - BRIDGMAN WH, Safta C, Ray J
A scalable variational method for estimating the latent infection-rate field of an outbreak.
PLoS One. 2026;21:e0350090.
PubMed Abstract available - STOTZER E, Graner S, Sengpiel V, Wessberg A, et al
Crisis leadership and strategic decisions in Swedish maternity care during the COVID-19 pandemic: A deductive analysis from the COPE staff project.
PLoS One. 2026;21:e0346625.
PubMed Abstract available - ADIGA A, Chopra A, Wilson ML, Ravi SS, et al
A high-resolution, US-scale digital similar of interacting livestock, wild birds, and human ecosystems for multihost epidemic spread.
Proc Natl Acad Sci U S A. 2026;123:e2507074123.
PubMed Abstract available - JUFUKU R, Shinchi H, Murata K, Chan M, et al
TLR7 ligand-cyclodextrin conjugate is a promising adjuvant for intranasal influenza vaccine.
Vaccine. 2026;86:128762.
PubMed Abstract available - LIU R, Fan Y, Xiong S, Lin J, et al
Drivers of and implementation strategies for influenza vaccination for cardiovascular populations in China: a scoping review.
Vaccine. 2026;86:128761.
PubMed Abstract available - OKUBO Y, Honjyo R, Uda K, Miyairi I, et al
Nationwide survey for household preparedness and vaccination acceptance during a novel influenza pandemic scenario in Japan, 2025.
Vaccine. 2026;86:128738.
PubMed Abstract available - MYBURGH L, van Loon K, Koetsier J, Hansen Q, et al
Conjugate vaccine technology enhances responses to influenza virus.
Vaccine. 2026;86:128728.
PubMed Abstract available - HALFMANN PJ, Duffy A, Wang T, Kawaoka Y, et al
Evaluating the immunogenicity of clade 2 and clade 3 sarbecovirus spike protein nanoparticle vaccines in Syrian hamsters.
Vaccine. 2026;84:128653.
PubMed Abstract available - LAMBERT D, Luisi N
Prevalence and correlates of COVID-19 vaccine uptake among sexual and gender minority adolescents in the southern United States.
Vaccine. 2026;84:128661.
PubMed Abstract available - SHEN Y, Shahn Z, Robertson MM, Gebo K, et al
Effect of a third COVID-19 vaccine dose on the incidence of Long COVID among adults who completed a primary vaccine series: a target trial emulation in a community-based cohort.
Vaccine. 2026;84:128666.
PubMed Abstract available - MULLER MP, Soe P, Shulha HP, Isenor JE, et al
mRNA COVID-19 vaccine safety in adults from the Canadian national vaccine safety network.
Vaccine. 2026;84:128630.
PubMed Abstract available - AMOAKO N, Cohuet S, Adjei MR, Gurry C, et al
COVID-19 vaccine effectiveness against severe acute respiratory infections (SARI) hospitalisations associated with laboratory-confirmed SARS-CoV-2 in Ghana, June 2022 to March 2024.
Vaccine. 2026 Feb 17:128310. doi: 10.1016/j.vaccine.2026.128310.
PubMed Abstract available - BALAM S, Kane F, Traore B, Konate D, et al
Kinetics and seroprevalence of anti-SARS-CoV-2 antibodies in vaccinated and unvaccinated health workers in Bamako, Mali, November 2021-February 2023.
Vaccine. 2025 Sep 1:127680. doi: 10.1016/j.vaccine.2025.127680.
PubMed Abstract available - GREY-JOHNSON M, Muhammad AK, Sillah F, Jones CJ, et al
COVID-19 testing acceptance among symptomatic individuals screened for a randomized clinical trial in The Gambia.
Vaccine. 2026;77 Suppl 1:127608.
PubMed Abstract available - ANYANGO RO, Nyawanda BO, Onyando BO, Haidara FC, et al
Factors associated with laboratory-confirmed SARS-Cov-2 infection among patients with severe respiratory illness (SRI): Findings from the COVID-19 vaccine effectiveness evaluation in Kenya and Mali, 2022-2023.
Vaccine. 2025 May 12:127234. doi: 10.1016/j.vaccine.2025.127234.
PubMed Abstract available - GURRY CE, Mwenda JM, Nardone A, Cohuet S, et al
Establishing the African region monitoring vaccine effectiveness (AFRO-MoVE) network for respiratory pathogens.
Vaccine. 2024 Dec 31:126616. doi: 10.1016/j.vaccine.2024.126616.
PubMed Abstract available - ONYANDO BO, Nyawanda BO, Onguru D, Haidara FC, et al
Factors associated with mortality among patients aged 12 years and above requiring hospitalization for severe respiratory illness (SRI): Findings from the COVID-19 vaccine effectiveness evaluation in Kenya and Mali, 2022-2023.
Vaccine. 2025 Mar 1:126910. doi: 10.1016/j.vaccine.2025.126910.
PubMed Abstract available - KUSEMERERWA S, Ankunda V, Ongaria TA, Abaasa A, et al
COVID-19 vaccination status and associated factors among patients presenting with COVID-19-like symptoms in Uganda.
Vaccine. 2025 Mar 6:126984. doi: 10.1016/j.vaccine.2025.126984.
PubMed Abstract available - ABAASA AM, Kusemererwa S, Ankunda V, Ongaria TA, et al
Effectiveness of COVID-19 vaccine against SARS-CoV-2 infection among symptomatic COVID-19 patients in Uganda.
Vaccine. 2025 Mar 6:126976. doi: 10.1016/j.vaccine.2025.126976.
PubMed Abstract available - SIKUVI K, Nghitukwa N, Kakehongo N, Katjitae I, et al
Effectiveness of COVID-19 vaccines against laboratory-confirmed SARS-CoV-2 infection amongst health workers, Windhoek, Namibia.
Vaccine. 2025 Mar 11:126977. doi: 10.1016/j.vaccine.2025.126977.
PubMed Abstract available - CRAWLEY AW, Murphy K, Plumb ID, Ocansey GA, et al
Challenges and enablers to establishing COVID-19 vaccine effectiveness studies in the World Health Organization Africa region: A mixed-methods evaluation of the African region monitoring vaccine effectiveness (AFRO-MoVE) network.
Vaccine. 2025 Mar 20:126823. doi: 10.1016/j.vaccine.2025.126823.
PubMed Abstract available - JOHNSTONE SL, Shapiro D, Chiwandire N, Matoti L, et al
Effectiveness of BNT162b2 and Ad26.COV2.S vaccines against COVID-19-related hospitalisation amongst adult members of a private health insurance plan in South Africa during the Delta and Omicron periods: A test-negative case-control study.
Vaccine. 2025 Apr 2:127068. doi: 10.1016/j.vaccine.2025.127068.
PubMed Abstract available - UNO N, Ross TM
Intramuscular administration of influenza hemagglutinin in one hind leg elicits similar protective immune responses as administration in two hind legs.
Virology. 2026;621:110961.
PubMed Abstract available - FARSIU N, Mahani FK, Arefinia N, Charostad J, et al
From Legacy to Innovation: A Comprehensive Review of Vaccine Platforms Against Viral Infections.
Virus Res. 2026 Apr 16:199730. doi: 10.1016/j.virusres.2026.199730.
PubMed Abstract available - VAN DIJK LLA, Rijsbergen LC, Havelaar AC, den Hartog Y, et al
Innate airway responses shape permissiveness to human respiratory syncytial virus.
Virus Res. 2026;368:199734.
PubMed Abstract available - JANGJOU A, Izadpanah P, Moqhadas M, Faramarzi H, et al
QT interval prolongation and its related factors before and after receiving lopinavir-ritonavir in the COVID-19 era: a historical cohort study.
Virus Res. 2026;368:199739.
PubMed Abstract available
Cell
No comments:
Post a Comment